Clinical trials: Advanced Gastrointestinal Cancer, active
Hepatocellular Carcinoma (HCC)
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
- Trial name
- NCT06860490
- Testing
- Sintilimab, Bevacizumab Biosimilar, HAIC
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Fudan University
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Hepatocellular Carcinoma (HCC)
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii.
- Trial name
- NCT07075120
- Testing
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Malignant Neoplasm of Stomach, Unspecified
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
HER2 is highly expressed on the surface of several cancer types, including breast and gastric/gastroesophageal junction (GEJ) cancers.
- Trial name
- NCT07333820
- Testing
- AB-201 Dose escalation
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Yonsei University
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Trial name
- NCT07890246
- Testing
- IM-1340
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread…
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma
- Trial name
- NCT03257761
- Testing
- Durvalumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Southern California
Gastric Cancer
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line treatment for advanced gastric cancer or…
- Trial name
- NCT06157996
- Testing
- lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
This is an open-label, single-arm, single-center clinical study to investigate the safety and efficacy of fuquinitinib combined with PD-1 inhibitors and first-line chemotherapy in the treatment of inoperable HER2-negative…
- Trial name
- G/GEJ cancer (NCT06158919)
- Testing
- Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and…
- Trial name
- NCT06761027
- Testing
- Anlotinib combined with Sintilimab
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Fujian Provincial Hospital
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric Cancer (Diagnosis), Gastric Cancer (GC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07502027
- Testing
- Iparomlimab and Tuvonralimab (QL1706)
- Volunteers
- 55 people
- Sponsor
- Huazhong University of Science and Technology
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable…
- Trial name
- NCT06022861
- Testing
- LY01015, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Peritoneal Carcinomatosis, Gastric Cancer
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients.
- Trial name
- GASPACCO (NCT04595929)
- Testing
- Staging laparoscopy, 5-Fluorouracil, Leucovorin
- Where
- Russia
- Volunteers
- 304 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chemo-refractory Colorectal Carcinoma
D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with histologically confirmed chemo-refractory colorectal carcinoma.
- Trial name
- MEFOX (NCT05212012)
- Testing
- Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
- Where
- 3 sites in Germany
- Volunteers
- 11 people
- Sponsor
- AIO-Studien-gGmbH
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.